Ameparomo Capsules 250 mg Drug Use Investigation

Pfizer

Status: Completed

Conditions: Intestinal Amebiasis

Study type: Observational

Funder types: Industry

Identifiers

NCT02680665

B3391001

Details and patient eligibility

About

This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg under actual medical practice.

Enrollment: 120 patients

Sex: All

Ages: 15 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with no history of using this product

Exclusion criteria

• No exclusion criteria are set out in this study.

Trial design